577953-88-9

Basic information

• Product Name: Montelukast Dicyclohexylamine Salt
• Synonyms: Montelukast raceMate;Montelukast Dicyclohexylamine Salt;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic N-Cyclohexylcyclohexanamine
• CAS NO: 577953-88-9
• Molecular Formula: C₁₂H₂₃N*C₃₅H₃₆ClNO₃S
• Molecular Weight: 767.50096
• Product Categories: Sulfur & Selenium Compounds;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 577953-88-9.mol
• Article Data: 20

Chemical Properties

• Melting Point: 65-67°C
• Boiling Point: 871.6°C at 760 mmHg
• Flash Point: 480.9°C
• Appearance: /
• Density: 1.2g/cm3 at 20℃
• Vapor Pressure: 1.83E-32mmHg at 25°C
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Montelukast Dicyclohexylamine Salt(CAS DataBase Reference)
• NIST Chemistry Reference: Montelukast Dicyclohexylamine Salt(577953-88-9)
• EPA Substance Registry System: Montelukast Dicyclohexylamine Salt(577953-88-9)

Safety Data

• Hazardous Substances Data: 577953-88-9(Hazardous Substances Data)

Usage

Chemical Properties

Pale Beige Solid

Uses

Montelukast Dicyclohexylamine Salt is a selective leukotriene D4-receptor antagonist. Used as an antiasthmatic.

InChI:InChI=1/C35H36ClNO3S.C12H23N/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);11-13H,1-10H2/b15-10+;/t32-;/m1./s1

Upstream product

• 101-83-7 N-cyclohexyl-cyclohexanamine 
• 158966-92-8 montelukast 
• 169954-93-2 2-(2-(3(S)-(3-(2-(7-chloroquinolin-2-yl)ethyl)phenyl)-3-(methanesulfonyl-1-oxy)methylethyl)phenyl)-2-propanol 
• 866923-62-8 2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile 
• 855473-51-7 1-(((1(R)-(3-(2(E)-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid methyl ester 
• 880769-28-8 2-(2-(3(S)-chloro-3-(3-(2-(7-chloro-2-quinolinyl)-(E)ethenyl)phenyl)propyl)phenyl)-2-propanol 
• 162515-68-6 1-(sulfanylmethyl)cyclopropaneacetic acid 
• 920739-17-9 (S)-benzenepropanol α-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy-1-methyl ethyl)-α-methane sulfonate 
• 807638-71-7 2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol 
• 880769-25-5 methyl 2-[(3S)-[3-[(2E)-(7-chloro quinolin-2-yl)ethenyl]phenyl]-3-chloropropyl]benzoate 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 149968-10-5 (E)-3-<2-(7-chloro-2-quinolinyl)ethenyl>-α-ethenylphenylmethanol 
• 142148-14-9 methyl 1-(acetylthiomethyl)cyclopropylacetic acid 
• 7073-69-0 2-(2-bromophenyl)propanol 

Downstream Products

• 151767-02-1 Montelukast sodium 
• 158966-92-8 montelukast 

Relevant articles and documents

A synthesis process of montelukast sodium (by machine translation)

A synthesis process of montelukast sodium, relates to the field of drug synthesis, adopts a double hydroxy precursor of a sulfonyl derivative, and mercapto carboxylic acid compound, b cyclohexylamine in the reaction under the action of a catalyst, to obtain the ammonium salt, the quaternary ammonium salt is converted into the montelukast sodium. Compared with the direct synthesis of montelukast sodium, synthetic ammonium salt reaction not only conversion is higher, but also easy to separate, high purity, thus being beneficial to obtain high-purity of montelukast sodium. The synthesizing process of the synthetic route is simple, easy to operate, low requirements on equipment, can realize the large-scale production of montelukast sodium. (by machine translation)

NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME

Disclosed are a novel montelukast 4-halobenzylamine salt, and a method for preparing a montelukast sodium salt by using the same. In the disclosed method, a montelukast 4-halobenzylamine salt represented by Formula 2 or a montelukast sodium salt represented by Formula 1 is prepared by obtaining a compound represented by Formula 3 from a compound represented by Formula 5, in the same reactor, without an additional obtaining process. In Formula 2, X represents F, Cl, Br or I.

NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME

Disclosed are a novel montelukast 4-halobenzylamine salt, and a method for preparing a montelukast sodium salt by using the same. In the disclosed method, a montelukast 4-halobenzylamine salt represented by Formula 2 or a montelukast sodium salt represented by Formula 1 is prepared by obtaining a compound represented by Formula 3 from a compound represented by Formula 5, in the same reactor, without an additional obtaining process. (Formular I and II should be inserted here) In Formula 2, X represents F, CI, Br or I.